Visterra announced on May 21, 2015 that it would partner with the Drug Discovery & Development (D3) unit under the Agency for Science, Technology, and Research (A*STAR) to develop VIS51, Visterra s neutralizing antibody meant to treat dengue fever. VIS513 is engineered using a humaniOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.